A pilot study conducted at a safety net hospital has armed researchers with a new educational tool: a digital app to persuade parents to vaccinate their adolescent against the human papilloma virus (HPV).
A pilot study conducted at a safety net hospital has armed researchers with a new educational tool: a digital app to persuade parents to vaccinate their adolescent against the human papilloma virus (HPV). The study, conducted at the Southern Methodist University, Dallas, Texas, found that the self-persuasion app, developed for both English and Spanish speakers, was feasible and changed parents’ decisions.
HPV infects a quarter of the US population, including teens, and according to the CDC, the virus can cause cervical, vaginal, and vulvar cancers in females; penile cancer in males; and anal cancer, back of the throat cancer, and genital warts in both genders. Existing public health efforts rely heavily on education messages and physician recommendations to persuade parents to vaccinate their adolescent children. Two shots of the vaccine, 6 to 12 months apart, is the recommendation for children in the 11-to-14-year age group; a third dose may be required if the first 2 doses are administered less than 5 months apart. For the 14-to-26-year age group, 3 shots over a 6-month period are recommended.
For their study, the authors enrolled 45 parents—a majority were mothers—who took their pre-teen and teenage children to safety net pediatric clinics. Parents were educated on the importance of HPV vaccination in the clinic’s waiting room via a customized application on an iPad. The software is designed for individuals to scroll through audio prompts that help them understand the importance of vaccination. A majority of the participants were Hispanic and had a high school education or less. However, since the app has a dual language option and is voice-based, illiteracy and language were not barriers for the study.
The parents rated the self-persuasion tasks as being easy to complete and helpful. Of the 33 parents with unvaccinated adolescents, 27 (nearly 82%) reported that the app had persuaded them to vaccinate their children.
“This approach is based on the premise that completing the vaccination series is less likely unless parents internalize the beliefs for themselves, as in ‘I see the value, I see the importance, and because I want to help my child,’” explained Austin S. Baldwin, PhD, the primary investigator of the study, in a press release.
While the parents were motivated to initiate the process, sustenance is the issue. Previous research by the group found that autonomous motivation was strongly correlated with parents’ intentions to vaccinate. “So they may get the first dose because the doctor says it's important,” Baldwin said. “But the second and third doses require they come back in a couple months and again in six months. It requires the parent to feel it’s important to their child, and that’s perhaps what’s going to push or motivate them to complete the series.”
These studies are part of a National Cancer Institute—funded research grant to develop patient education software for the HPV vaccine that is easily used by low-income parents who may struggle to read and write, and speak only Spanish.
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer
October 22nd 2024By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More